Pharmaceutical company OncoZenge AB (publ) (STO:ONCOZ) announced on Friday plans to partner with Pharmanovia for exclusive commercialization rights of BupiZenge in Europe, the Middle East, and Northern Africa (EMENA).
A non-binding offer has been signed, initiating a period of exclusivity for due diligence and joint planning, with a goal to finalize the agreement by 30 November 2024. The partnership includes potential milestone payments of up to EUR7m to support Phase 3 trials and commercialization. Additional commercial milestone payments and royalties on sales are part of the agreement. Pharmanovia will leverage its regulatory and market expertise to facilitate the clinical program and market entry.
OncoZenge is preparing to appoint a CDMO and begin technology transfer for Phase 3 lozenge production, targeted for early 2025. A CRO will be appointed after the Phase 3 study protocol is finalized. BupiZenge, an oral lozenge of bupivacaine, is aimed at treating oral mucositis, a severe pain condition affecting cancer patients. Phase 2 trials showed significant pain relief compared to the current standard of care.
Ananda's cannabinoid medicines to feature in NHS epilepsy trials
AstraZeneca's Wainzua recommended for EU approval
Avacta Group partners with Tempus to enhance AI-driven oncology drug development
PharmaLogic opens new radiopharmaceutical facility in Salt Lake City
Astellas Pharma's VYLOY receives US FDA approval
Foresee Pharmaceuticals completes linvemastat (FP-020) phase clinical study in Australia
Ionis and AstraZeneca's WAINZUA recommended for EU approval
Novartis receives positive CHMP opinion for Kisqali
OncoZenge partners with Pharmanovia for exclusive BupiZenge commercialization in EMENA regions
SHINE Technologies collaboration could result in new kidney and prostate cancer treatments
Elysium Health launches VISION for visual performance and eye health
IgGenix doses first patient in IGNX001 ACCELERATE Peanut Phase 1 trial
Innovent Biologic meets primary endpoint in picankibart phase 2 study